Matthew Davids, MD from Dana-Farber Cancer Institute, Boston, MA outlines the poster demonstrating preliminary results from an investigator initiated study looking at the BTK inhibitor ibrutinib given in combination with FCR chemotherapy as a first line therapy in patients 65 years or younger. Results have shown very good tolerability and good levels of minimal residual disease (MRD) negativity. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Preliminary results of ibruntinib in combination with FCR chemthererapy.
